MetaVia rises as it starts higher-dose obesity drug study

MetaVia

10/04/2026 13:44

** Shares of MetaVia MTVA.O rise 4% to $2.08 premarket

** Biotech firm says it dosed the first patient in a higher-dose study of its experimental obesity drug DA-1726

** The early-stage study will test two ways to step patients up to higher weekly doses of the drug, up to 64 mg, in 40 obese but otherwise healthy adults - MTVA

** Firm says earlier data showed about 9% weight loss at a 48 mg dose, along with better blood sugar control and signs of improved liver health

** Adds that DA-1726 targets two appetite and energy-control hormones and is given as a weekly injection

** Results are expected in the fourth quarter of 2026

** As of last close, stock down ~1% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))